ArticleInternational journal of immunopathology and pharmacology
Combinatory treatment using tacrolimus and a STAT3 inhibitor regulate Treg cells and plasma cells.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives.Frontiers in pharmacology · 2026Review
- Bridging B-cell autoimmunity and oncology: the PD-1/PD-L1 paradox in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy.American journal of translational research · 2026Article
- The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2025Review
- The effects of interleukin-21 in the biology of transplant rejection.Frontiers in immunology · 2025Review
- Review
- Cholinergic anti-inflammatory pathway ameliorates murine experimental Th2-type colitis by suppressing the migration of plasmacytoid dendritic cells.Scientific reports · 2022Article
- The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches.Journal of clinical medicine · 2021Review
- T Cells in Systemic Lupus Erythematosus.Rheumatic diseases clinics of North America · 2021Review
- Article
- STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.Cancers · 2019Review
- Dose-dependent effects of oleuropein administration on regulatory T-cells in patients with rheumatoid arthritis: An in vitro approach.International journal of immunopathology and pharmacologyArticle
- Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE; lupus) is a prototypical autoimmune disease characterized by circulating autoantibodies to nuclear antigens and immune complex deposition, resulting in damage to target organs. To investigate the effects of tacrolimus (TAC) on effector T cells and B cells, we examined its involvement in the development of effector T cells, germinal center (GC) B cells, and plasma cells in an in vitro system using wild-type (WT) and lupus-prone mice. The population of T helper (Th) 1, Th2, and Th17 cells interleukin (IL)-17-producing T (Th17) cells and the production of interferon-γ and interleukin-17A IL-17A were suppressed by TAC. TAC also reduced the population of regulatory T (Treg) cells; however, a combination treatment with the signal transducer and activator of transcription 3 (STAT3) inhibitor STA-21 promoted the population of Treg cells. TAC also suppressed the populations of GC B cells and plasma cells synergistically with STA-21. These findings suggest that the application of TAC with a STAT3 signal inhibitor may provide benefits in SLE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.